These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29605883)

  • 21. In Vivo Generation of CAR T Cells Selectively in Human CD4
    Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
    Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.
    Zebley CC; Brown C; Mi T; Fan Y; Alli S; Boi S; Galletti G; Lugli E; Langfitt D; Metais JY; Lockey T; Meagher M; Triplett B; Talleur AC; Gottschalk S; Youngblood B
    Cell Rep; 2021 Nov; 37(9):110079. PubMed ID: 34852226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
    Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
    J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient derivation of chimeric-antigen receptor-modified T
    Kranz E; Kuhlmann CJ; Chan J; Kim PY; Chen ISY; Kamata M
    Front Immunol; 2022; 13():877682. PubMed ID: 35967430
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
    Lapteva N; Gilbert M; Diaconu I; Rollins LA; Al-Sabbagh M; Naik S; Krance RA; Tripic T; Hiregange M; Raghavan D; Dakhova O; Rouce RH; Liu H; Omer B; Savoldo B; Dotti G; Cruz CR; Sharpe K; Gates M; Orozco A; Durett A; Pacheco E; Gee AP; Ramos CA; Heslop HE; Brenner MK; Rooney CM
    Clin Cancer Res; 2019 Dec; 25(24):7340-7350. PubMed ID: 31558475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
    Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
    Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.
    Zhang Q; Hu H; Chen SY; Liu CJ; Hu FF; Yu J; Wu Y; Guo AY
    Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):190-200. PubMed ID: 31201998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
    Talleur AC; Qudeimat A; Métais JY; Langfitt D; Mamcarz E; Crawford JC; Huang S; Cheng C; Hurley C; Madden R; Sharma A; Suliman A; Srinivasan A; Velasquez MP; Obeng EA; Willis C; Akel S; Karol SE; Inaba H; Bragg A; Zheng W; Zhou SM; Schell S; Tuggle-Brown M; Cullins D; Patil SL; Li Y; Thomas PG; Zebley C; Youngblood B; Pui CH; Lockey T; Geiger TL; Meagher MM; Triplett BM; Gottschalk S
    Blood Adv; 2022 Nov; 6(21):5737-5749. PubMed ID: 35446934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.
    Tang D; Zhao L; Yan F; Ren C; Xu K; Zhao K
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.